Industry Co-Chair

APEC Biopharmaceutical Working Group on Ethics

Thomas B. Cueni is Director General of IFPMA, the global association of pharmaceutical research companies, based in Geneva and is Secretary of the global Biopharmaceutical CEO Roundtable (BCR). In this capacity, Thomas Cueni was instrumental in creating the AMR Action Fund. A ground-breaking partnership, launched in 2020, that has raised nearly $1 billion to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR.

Thomas Cueni represents the innovative biopharmaceutical industry on the ACT Accelerator, the Access to COVID-19 Tools (ACT) Accelerator, a unique global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines. Thomas Cueni is Chair of the Business at OECD Health Committee, and also serves on the Board of Directors of the City Cancer Challenge (CCan), an initiative aiming to improve cancer care in major cities in low- and middle-income countries. Cueni also serves as Industry Co-Chair of the APEC Biopharmaceutical Working Group on Ethics. Furthermore, he is Chair of the Board of the cross-sectoral AMR Industry Alliance, a group committed to tackling the threat of antimicrobial resistance, which includes more than 100 companies and associations representing Rx pharma, generics, biotech, and diagnostics.

Prior to joining IFPMA he was Secretary General of Interpharma, the association of pharmaceutical research companies in Switzerland, and for many years was a member of the Board and Chair of a key committee of the European Federation of Pharmaceutical Industries and Associations. Prior to his appointment with Interpharma, Thomas Cueni had a career as a journalist, inter alia as London correspondent for the “Basler Zeitung” and “Der Bund”, and he served as a Swiss career diplomat with postings in Paris (OECD) and Vienna (IAEA, UNIDO). He studied at the University of Basle, the London School of Economics, and the Geneva Graduate Institute for International Studies, and has Master degrees in economics (University of Basel) and politics (London School of Economics, LSE).

Pamela Fralick is an experienced leader who has been fostering positive change in Canada’s health sector for decades. Throughout her career, Ms. Fralick has distinguished herself in a variety of senior roles. A convener and innovator, Ms. Fralick is one of Canada’s leading, compassionate voices in the health sector. As the President of Innovative Medicines Canada, Ms. Fralick leads the industry association for Canada’s innovative pharmaceutical companies, working with its members and communities to ensure Canadians have access to the medicines they need when they need them.

Prior to joining Innovative Medicines Canada, Ms. Fralick was President and CEO of the Canadian Cancer Society, Canada’s largest health charity, where she oversaw a process of intense transformation, resulting in historic changes to the operational and governance structures of the organization.

Ms. Fralick previously served as president and CEO of the Canadian Healthcare Association (CHA), the Canadian Physiotherapy Association, the Collegium of Work and Learning and the Canadian Centre on Substance Abuse. At each organization, Ms. Fralick led initiatives designed to enhance sustainability and improve outcomes for their members and stakeholders. Ms. Fralick has also held senior public service positions with Health Canada and the Department of National Defense.

True to her commitment to the health and well-being of Canadians, Ms. Fralick has served on numerous prestigious boards and collaboratives across Canada. She was Chair of the Health Action Lobby (HEAL) and Co-chair of the Canadian Coalition for Public Health in the 21st Century (CCPH21). She has been active in many organizations as a senior volunteer, including the Centre for Addiction and Mental Health (Chair), the University of Ottawa Institute of Mental Health Research, Triathlon Canada, the International Triathlon Union as well as the Outward Bound Canada (Chair) and the Canada Dance Festival (Chair). She currently serves on the Board of Outward Bound International and the Global Advisory Council of the Commission on Accreditation of Healthcare Management Education (CAHME).

Ms. Fralick has a BA in French and psychology and an MA in developmental psychology from Carleton University, as well as a Master of Public Administration (MPA) from Queen’s University. She also holds an ICD.D designation. She is trilingual – in English, French and German – and is an accomplished artist and athlete.

Ms. Andrea Clements joined the Canadian Embassy in August 2022 as head of the Commercial Policy and International Business Development (CPIBD) team. She oversees a diverse team of trade & FDI promotion, defence trade policy, Science & Technology, and Space Affairs officers, counsellors and leaders.

Ms. Clements joined the Canadian Foreign Service and has been with the Global Affairs Canada’s Trade Commissioner Service for over 22 years. Her leadership and insight to trade and international business development are invaluable.

From 2019 to 2022 she was Director, High Intensity Services Division at Headquarters where she worked on developing programming for high growth, high potential Canadian companies. Prior to that, Ms. Clements was Director, Aerospace, Automotive, Defence and ICT Practices Division.

Ms. Clements has served at the Canada Embassies in Japan and South Korea and the Canadian Consulate in Fukuoka, Japan. In addition to English and French, she speaks fluent Japanese.

Dr. Otmar Kloiber is the Secretary General of the World Medical Association. He has been an international medical relations and collaboration leader for more than 20 years, with expertise in medical ethics, health policy, government affairs and management of relationships with patients, other health professionals, manufacturers and other medical stakeholders. He has been the chief executive of the WMA since 2005.

Prior to his move to the WMA, between 1997 and 2005, Otmar served as Deputy Secretary General and Secretary of the German Medical Association. During his tenure there, he was selected as a Member of the Study Commission on the Law and Ethics of Modern Medicine of the German Bundestag (Parliament), 14th electoral term.

Between 1991 and 2005, he was also a key liaison to the Standing Committee of European Doctors, the WMA, the International Conference of Medical Chambers, the European Forum of the World Health Organization and individual national medical associations. In addition, for six years, he was the foreign relations adviser to the German Medical Association, focusing on international health and social policy reforms and construction of the German Health Network.

Otmar holds an MD (1984) and PhD (1986) from University of Cologne, was a postdoctoral fellow in the Department of Biochemistry at the University of Minnesota, and was a research assistant at the Max Planck Institute for Neurological Research, engaged in pathophsyiological studies on brain energy metabolism and cerebral blood flow.

In 2006, he was awarded an honorary doctorate by the Victor Babes University for Medicine and Pharmaceutics, Timisoara, Romania. He is Clinical Professor in Health Administration at the Brooks College of Health, University of North Florida.

Matt Murray was appointed as the U.S. Senior Official for Asia-Pacific Economic Cooperation (APEC) in February 2022. In this role, he coordinates U.S. participation in APEC and also oversees the Office of Economic Policy in the State Department’s Bureau of East Asian and Pacific Affairs.

Prior to his current assignment, Matt led the State Department’s Bureau of Economic and Business Affairs (EB) as Senior Bureau Official from August 2021 to January 2022, and he served as Deputy Assistant Secretary of State for Trade Policy and Negotiations from September 2020 to August 2021.

Matt has focused on U.S. economic engagement with the Asia Pacific region throughout his State Department career, including as Minister Counselor for Economic Affairs at the U.S. Embassy in Beijing, Counselor for Economic Affairs at the U.S. Embassy in Canberra, and Special Assistant for East Asian and Pacific issues in the Office of the Under Secretary for Economic Growth, Energy and Environment.

Matt is a Senior Foreign Service Officer who also has served overseas in Beijing, Shanghai, Dar es Salaam and New Delhi and in Washington, D.C. as Director of the 24/7 Watch in the Bureau of Intelligence and Research. He has master’s degrees from the U.S. Army War College and the University of Pittsburgh and a bachelor’s degree from Washington College in Chestertown, Maryland.

Secretary Blinken announced Richard Nephew as the Department of State’s Coordinator on Global Anti-Corruption on July 5, 2022. Nephew is returning to the Department from Columbia University’s Center on Global Energy Policy, where he was a Senior Research Scholar. He is a published author, including of a book, chapters for edited volumes, and articles on sanctions, deterrence, and nuclear proliferation. Prior to his tenure at Columbia, Nephew served as deputy special envoy for Iran, Principal Deputy Coordinator for Sanctions Policy, and Director for Iran on the National Security Staff. He also served in the Department’s Bureau of International Security and Nonproliferation, as well as in the Office of Nonproliferation and International Security at the Department of Energy. Nephew holds an MA in Security Policy Studies and a BA in International Affairs from The George Washington University.

Tricia Van Orden is the Director of the Trade Promotion Coordinating Committee Secretariat (TPCC) for the International Trade Administration (ITA). In this role, she coordinates trade promotion strategies with 20 federal agencies as well as states and localities to expand the number and diversity of U.S. businesses that successfully compete in global markets, in order to accelerate firm-level growth, expand employment, and contribute to equitable local and regional economic development. With a focus on small business export promotion, Van Orden also serves as the U.S. delegate to the Asia-Pacific Economic Cooperation (APEC) Small and Medium Enterprises Working Group. Additionally, she is responsible for coordinating women’s economic empowerment activities across ITA, and she leads the Gender Committee of the Department of Commerce’s Equity Council. 

Van Orden has held several positions at ITA. She directed the President’s Export Council and the President’s Advisory Council on Doing Business in Africa. She also served as the Canada Desk Officer, where she was responsible for increasing access to the Canadian market for U.S. businesses.  Van Orden started at ITA as a Presidential Management Fellow in the Office of the Western Hemisphere, where she lead efforts to promote business ethics and corporate social responsibility programs among local business communities throughout Central America and the Caribbean.

Van Orden has also worked at the Inter-American Development Bank, where she led programs to increase the capacity of small businesses to access capital. She started her career as an aide in the U.S. Senate covering foreign affairs and international trade. Van Orden earned a Bachelor of Arts in economics from Colorado State University, a Bachelor of Arts in political science from the University of Washington, and a master’s in public policy from George Mason University.  

Tan Sri Datuk Rebecca Fatima Sta Maria is the executive director of the APEC Secretariat based in Singapore, which serves as advisory body, implementation arm and custodian of institutional memory for the 21-member economies that make up the APEC forum. Dr Sta Maria was a top-level Malaysian civil servant and trade negotiator. As Secretary-General of the Malaysian Ministry of International Trade and Industry from December 2010 to July 2016, she oversaw the formulation of Malaysia’s international trade policies and positions. She often took the lead in their implementation as chief negotiator for bilateral and regional free trade agreements such as the Trans-Pacific Partnership and the Regional Comprehensive Economic Partnership. Dr Sta Maria played an integral role in Malaysia’s participation in multilateral forums such as APEC, where she often represented her economy during the APEC Ministers’ Responsible for Trade Meetings and the Small and Medium Enterprises Ministerial Meetings. In the Association of Southeast Asian Nations (ASEAN), Dr Sta Maria chaired the body that drafted the ASEAN Economic Community 2015 Blueprint as well as the ASEAN Economic Community 2025 Blueprint.

An accomplished academic and writer, Dr Sta Maria’s scholarship has been recognized through awards from the American Academy of Human Resource Development and from the University of Georgia. In 2017, she authored a book about her personal slice of Malaysian heritage and cuisine, called The Smell of Home. Before 2010, the position of executive director of the APEC Secretariat rotated yearly among officials assigned by the incumbent host economy. Starting in 2010, the appointment was opened to applications from highly qualified professionals who will, when appointed, lead the Secretariat in fixed three-year terms with an option to renew. Dr Sta Maria is the first woman executive director of the APEC Secretariat.

President of Farmoquímica del Pacífico 

Company founded in 1834 in Valparaíso, Chile. During our long history the goal has always been to help improve the quality of life of people through our differentiated healthcare solutions. Our focus is to create trust and bring innovation to the people through three channels, physicians, pharmacies and direct to patients, all related to everyday health problems.

President of Cámara Nacional de Laboratorios A.G.

Association that congregates laboratories preponderantly from national capitals. Most were founded in the nineteenth and twentieth centuries in Chile. Its history has demonstrated the commitment to the health of the people that live in Chile and the main motivation is to consolidate its presence in the pharmaceutical market through improving access of the population to quality medicines at fair value, searching always for an ethical excellence.

Member of the Chilean Consensus Framework

Engineer from Universidad de Chile

Sabrina is the Senior Executive Director of the Hong Kong Association of the Pharmaceutical Industry (HKAPI); member of the High Level Steering Committee on Antimicrobial Resistance and member of Business Facilitation Advisory Committee, the government of Hong Kong Special Administrative Region; Chair of Advisory Board of the HKU Bachelor of Pharmacy Program, The University of Hong Kong; and member of APEC Biopharmaceutical Working Group on Business Ethics.

Adrian is the Chair of the Australian Ethical Health Alliance following its formation in 2019. Adrian has lead Australia's nationwide and sector wide inclusion of participants in AEHA with 78 participating parties, reportedly still the largest ethical alliance of its type globally. Adrian is also the CEO of the Australian Orthopaedic Association.

Connie Côté has been involved in the not-for-profit, regulatory and charitable health sector for over twenty years and is currently the Chief Executive Officer of the Health Charities Coalition of Canada (HCCC).  Her priorities at HCCC include advocating on behalf of the sector on issues related to health research and health policy, pursuing partnerships and promoting voice of patients. She is passionate about systems perspectives and seeks ways of working collaboratively to identify new solutions. 

Prior to joining HCCC, Connie worked with the Canadian Lung Association where she held various management positions, including leading the National Lung Health Framework. Previously, she worked for the Federation of Medical Regulatory Authorities of Canada and the Royal College of Physicians and Surgeons of Canada.

She holds a Master of Human Systems Intervention from Concordia University and volunteers with various organizations including as Chair of the Canadian Longitudinal Study on Aging Advisory Council.

Since August 2021, Terry Cowl has been the Executive Director of the Trade Strategy and Responsible Business Conduct division at Global Affairs Canada.  Terry’s team leads on Canada’s Responsible Business Conduct (RBC) policy and programming and provides strategic advice concerning the Trade Commissioner Service of Canada in areas such as supply chain management and trade diversification.

Prior to his current role, Terry was Consul and Senior Trade Commissioner at the Consulate General of Canada – San Francisco/Silicon Valley (2017-2021).  Terry’s teams in SF and Palo Alto supported Canadian entrepreneurs seeking technology and investment partnerships with firms in the Bay Area as well as supporting foreign direct investment from Northern California and Hawaii into Canada.  

His earlier assignments at Global Affairs Canada include Director of Economic Analysis and Coordination Division, Deputy Director of the North America Commercial Relations Section and Economic Advisor for the North America Bureau.  From 2007-2010, Terry served as Canada's ASEAN Regional Economic Advisor, based out of the High Commission of Canada in Singapore.   

Before joining Global Affairs Canada, he held positions in other portfolios within the federal government - such as the Privy Council Office, Natural Resources Canada and Canadian Heritage.  Originally from Nova Scotia, Terry holds a Masters degree in International Affairs (Carleton), a Masters degree in Political Science (Waterloo) and a Bachelors degree in Political Science (Acadia).

Member

Chief Ethics & Compliance Officers Roundtable, IFPMA 

Cari Gallman, chief compliance and ethics officer, is responsible for reinforcing the company’s strong culture of ethics and integrity; she champions efforts that ensure our operations are conducted in compliance with ethical business practices, our Principles of Integrity, and laws and regulations in the global markets in which we operate. In addition to reporting to the General Counsel and CEO, Cari also reports to the Chair of the Audit Committee of the Board of Directors.

“Our deep and unwavering commitment to ethics and integrity provides the foundation for everything we do. It guides how we interact with our colleagues and external partners, as well as the work we do on behalf of our patients and communities around the world,” she says.

Cari has 15 years of combined experience in pharmaceutical law and compliance. She began her legal career in private practice representing pharmaceutical and medical device manufacturers in government enforcement and regulatory matters. In her practice, she regularly advised companies on how to design and implement robust compliance policies to meet business objectives as well as legal needs. She joined the company in 2015 and assumed positions of increasing responsibility, including as head of the legal team supporting the Global Oncology Commercialization and Development organizations. 

She earned a bachelor’s degree in political theory from Princeton University and a JD from Harvard Law School.

Vitor Geromel is a legal analyst in the OECD Anti-Corruption Division and works on promoting OECD standards on anti-corruption and business integrity through global partnerships. He is also co-author of the OECD Toolkit on raising awareness and preventing corruption in SMEs. Additionally, Vitor has participated in several OECD Working Groups on Bribery, country monitoring evaluations of the implementation of the OECD Anti-Bribery Convention, and related instruments.

Vanessa Hans is Head of Private Sector at the Basel Institute on Governance. She has held the position since July 2022, having first joined the Basel Institute in January 2020 as Private Sector Specialist.

Prior to joining the Institute, Vanessa was the Managing Director of the French Chamber of Commerce and Industry in the Philippines. She has several years of experience advising companies on corporate social responsibility as well as international development strategies. 

Vanessa holds a Bachelor of Business Administration from HEC Montreal and a Masters in Corporate Social Responsibility from the University of Nottingham.

Hovard serves as Chief Executive Officer for Neuspera Medical, a medical device company developing implantable medical device technology for patients with chronic illness. He previously served as the President of Coloplast Interventional Urology, with leadership responsibility for four business areas within urological devices including 900 employees across 19 economies. Hovard also serves as a board member for several companies in the medical device industry.

He holds Bachelor and Master Degrees in marketing & strategy from Copenhagen Business School in Denmark.

Member

Chief Ethics & Compliance Officers Roundtable, IFPMA

Lisa LeCointe-Cephas manages a team of lawyers around the world who are responsible for conducting internal investigations related to breaches of Merck’s policies, the Foreign Corrupt Practices Act, international anti-bribery and anti-corruption laws, and False Claims Act cases. Her team also leads the company’s response to government and regulatory proceedings around the world. She provides counsel to the company with respect to cybersecurity threats and data loss protection, and proudly serves as an international pro-bono coordinator for Merck. 

Ms. LeCointe-Cephas joined Merck in February 2018 from Bristol-Myers Squibb Corp. (“BMS”), where she served as the lead Government Investigations counsel. Prior to BMS, she was a partner in the Government Investigations and White-Collar Defense practice of Kirkland & Ellis LLP, New York.

Ms. LeCointe-Cephas received her B.A. from Yale University and received her J.D. from Columbia Law School.

Member

Chief Ethics and Compliance Officers Roundtable, IFPMA

Mwana Lugogo is Chief Ethics & Compliance Officer, Takeda and Chair of the IFPMA Ethics & Business Integrity Committee and Chief Ethics & Compliance Officers Roundtable since January 2023. She is passionate about strengthening the ethics-based culture at Takeda and bringing its values to life, as part of Takeda’s commitment to patients, to each other and to society. Mwana joined Takeda in 2012 to establish the Compliance function for the Growth & Emerging Market Business Unit and spearheaded the development of a full scope Ethics and Compliance program for the BU, with an emphasis on good internal corporate governance, and built a strong ethical business culture. She was appointed to lead the newly-created Global Ethics & Compliance organization in 2015, joining the Takeda Executive Team in January 2019.

Member

Chief Ethics & Compliance Officers Roundtable, IFPMA

As Global Chief Compliance Officer, Jennifer is passionate about working with businesses through partnership and collaboration, thinking together how best to approach decisions while mitigating risk. With a purpose to empower and inspire, Jennifer strives to create an environment where people have the freedom to operate and ultimately achieve their full potential.

At a global level, Jennifer leads the effort to ensure that all parts of the business understand the nuances of operating within our code of conduct through a comprehensive Ethics and Compliance Program, designed and implemented to adhere to industry best practices and current government guidance. Additionally, she oversees US Corporate Affairs, a function comprising Government Affairs, Corporate Communications, Patient Advocacy, and Stakeholder Management.

Jennifer joined Otsuka in January 2011 as Senior Compliance Counsel and assumed the responsibilities of Chief Compliance Officer in May 2015. Prior to joining Otsuka, she worked as a litigator at a multinational law firm, focusing on defending pharmaceutical and medical device manufacturers in government investigations and lawsuits. She also served on active duty in the US Army for more than 13 years, trying more than 70 felony criminal trials. Jennifer then served in the US Army Reserve for an additional 13 years, retiring in 2017.

Jennifer earned her bachelor’s degree from St. Lawrence University and her JD from the University of Maryland School of Law.

María Liliana Mor is the Director of Strategic Partnerships and Development of Pro Mujer. She fosters alliances and structures financial vehicles to promote women’s financial inclusion, impact investing, entrepreneurship, and health in the region.

María is an international specialist who has made relevant efforts in social impact development, which includes partnerships with Corporate Social Responsibilities and Sustainability teams from Multinational Companies, Government Entities, and Multilateral Organizations. Her knowledge focuses on vulnerable communities, community-based growth, humanitarian assistance and the future of work.

Mor has 17 years of experience in consulting, project management and strategic practices on international development. Her previous experiences include the Inter-American Development Bank, the World Bank and the Pan-American Health Organization.

Recently, she supported the Education Division at the Inter-American Development Bank where she was in charge of leading the 21st century skills agenda. Mor´s work was focused on strengthening learning ecosystems to equip Latin American and Caribbean citizens with transversal skills, in partnership with the public and private sector stakeholders.

María has worked at The Trust for the Americas-Organization of American States for 12 years. She led the implementation of innovation, open government, economic opportunities, and technology for good social programs in 21 Latin American and Caribbean countries. In addition, Mor directed the institutional initiative to bring gender and accessibility perspectives to all of these projects.

Mor holds a B.A. in Government and Foreign Affairs from Universidad Externado de Colombia and an M.A. in Public Administration and International Development Management from American University.

Sofie Melis joined IFPMA in September 2016. She leads its Ethics and Compliance portfolio, which includes the global implementation of the IFPMA Code of Practice and the management of the Ethics & Business Integrity Committee (eBIC). As from July 2020, her role was extended to include strategic HR responsibilities. In the last 8 years of her career, Sofie has worked in corporate compliance for both Eli Lilly and Biogen Idec. Prior to that she held several roles in HR training & development in the banking, electronics and consulting industry. Just before joining IFPMA, Sofie completed a one-year assignment with the International Committee of the Red Cross as Head of HR Compliance. Sofie holds a master’s degree in Languages and Literature, a bachelor in HR Management, a post-master’s in Adult Education and a certificate in International Compliance and Ethics.

Ida Nassar, Esq. is Vice President, Assistant General Counsel, Ethics & Compliance for the Advanced Medical Technology Association (AdvaMed) in Washington, D.C.

Ms. Nassar manages AdvaMed’s ethics and compliance policy working groups on the AdvaMed Code, federal and state anti-kickback statutes, the Physician Self-Referral (Stark) Law, Sunshine Implementation, False Claims Act, and other health care laws and regulations applicable to medical device innovators and manufacturers. Ms. Nassar also handles AdvaMed’s global legal policy working groups, which seek to establish common global standards for anti-corruption and business integrity and secure procurement, regulatory, and enforcement incentives that reward compliance.

Prior to AdvaMed, Ms. Nassar was a Senior Attorney within the Drug Enforcement Administration’s Office of Chief Counsel where she handled enforcement actions under the Controlled Substances Act as well as defensive litigation matters for the department. She also served as Trial Attorney for the U.S. Department of Justice managing commercial and torts litigation (including vaccine litigation). Ida also practiced for several years at a law firm managing life sciences products liability litigation.

Co-Chair

Multilateral Organizations Working Group, IFPMA

Chrisoula’s successful career is highlighted by creative citizen mobilization, coalition-building and the development of ethical practices on a provincial, national and international level. She has built a world-class understanding of the issues and challenges facing the advancement of ethical policies. She has played a pivotal role in the advancement of compliance and ethics on the international level through her leadership in the Code Compliance Network at the IFPMA and as a member of the leadership team in the APEC SME Ethics Initiative in 21 countries of the Asia Pacific region.  In her current role she heads the global ethics and compliance policy and industry shaping department at Takeda Pharmaceuticals.

Keita Otsubo is the Acting Secretary General of the Japan Patients Association (JPA). Since 2017, he started working as a secretariat staff member of JPA, mainly coordinating with the Ministry of Health, Labor, and Welfare, Diet members, and pharmaceutical companies. He has been serving as Acting Secretary General since May 2023.

A commercially focused executive with broad health sector experience. Cushla is currently CEO of the NZ Medical Technology Association and has previously held senior positions in Procurement, Clinical Research, Human Resources and Supply Chain, originally starting her career as a Registered Nurse.

Cristóbal Thompson is the Executive Director at AMIIF (Asociación Mexicana de Industrias de Investigación Farmacéutica (AMIIF)). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine.

Thompson is a Bicultural Executive with 30 years of experience in Marketing, Sales, Business Development and as a General Manager in Consumer, OTC & Pharma Companies.

Julie Wagner is Senior Assistant General Counsel and Head of Global Ethics, Compliance and Enforcement Legal Policy at PhRMA, with responsibility for helping to shape PhRMA advocacy and drive member consensus on issues related to federal enforcement of fraud and abuse laws, compliance policy, and global ethics issues.

Prior to joining PhRMA, Julie served as Senior Counsel within the U.S. Department of Health and Human Services Office of Inspector General, serving as an Anti-Kickback Statute subject matter expert and advising the OIG, CMS Innovation Center, prosecutors and industry on health care fraud and abuse matters.

Kathryn E. Wengel (Kathy) is Executive Vice President, Chief Technical Operations & Risk Officer for Johnson & Johnson, and a member of the Company’s Executive Committee. She has significant healthcare, operations and global business expertise – with more than three decades of experience in leadership positions at Johnson & Johnson.

In her current role, Kathy is responsible for the continued strengthening of the Company’s core technical operations and risk management capabilities. She leads key technical operations functions, including: Procurement, Engineering & Property Services, Sustainability and cross-sector Supply Chain teams focused on standards, services, strategic programs and data science, as well as critical risk functions, including: Quality & Compliance, Health Care Compliance, Environmental Health & Safety, Global Security and Global Brand Protection. A strong developer of globally diverse teams, Kathy also plays an important role with external stakeholders to advance critical risk management, resilience and technical operations priorities on behalf of Johnson & Johnson and the healthcare industry.

Most recently, Kathy served for nine years as Executive Vice President and Chief Global Supply Chain Officer, and prior to that, as the Company’s first Chief Quality Officer. Under her leadership, Johnson & Johnson has become the only healthcare company ever ranked among the top five on the Supply Chain Top 25 list by Gartner, Inc. – a ranking that recognizes the critical role its Supply Chain has played as an integrator across an ecosystem of internal and external partners.

Externally from Johnson & Johnson, Kathy serves as a member of the Board of Directors at the Laboratory Corporation of America Holdings (Labcorp), a leading global life sciences company. She is the Vice Chair of the Board of Directors at the National Association of Manufacturers in the U.S. She also serves as Chair of the Board of GS1 Global, a nonprofit that develops and maintains global supply chain standards. Within Johnson & Johnson, Kathy is executive sponsor for the Women’s Leadership & Inclusion (WLI) initiative and the Women in Science, Technology, Engineering, Math, Manufacturing and Design (WiSTEM2D) program.

In 2019, Kathy was recognized by the Council of Supply Management Professionals (CSCMP) with its lifetime Distinguished Service Award, and she was elected to the Supply Chain Hall of Fame, the industry’s top individual supply chain honor. In 2015, Kathy received the National Association of Female Executives’ (NAFE) Women of Excellence Award.

Kathy holds a BSE degree in civil engineering and operations research from Princeton University.